These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37194780)

  • 1. THE EVALUATION OF INFLIXIMAB TROUGH LEVEL FAVORS MAINTENANCE THERAPY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE.
    Kampa KC; Loures MR; Ivantes CAP; Petterle RR; Pedroso MLA
    Arq Gastroenterol; 2023; 60(1):48-56. PubMed ID: 37194780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease.
    Hoekman DR; Brandse JF; de Meij TG; Hummel TZ; Löwenberg M; Benninga MA; D'Haens GR; Kindermann A
    Scand J Gastroenterol; 2015; 50(9):1110-7. PubMed ID: 25865965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosing interval and diagnosis predict infliximab levels in patients with inflammatory bowel disease on maintenance treatment.
    Krajcovicova A; Batovsky M; Gregus M; Hlista M; Durina J; Leskova Z; Sturdik I; Gojdic M; Jalali Y; Koller T; Toth J; Huorka M; Hlavaty T
    Acta Gastroenterol Belg; 2018; 81(4):465-470. PubMed ID: 30645913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study.
    Paul S; Del Tedesco E; Marotte H; Rinaudo-Gaujous M; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Roblin X
    Inflamm Bowel Dis; 2013 Nov; 19(12):2568-76. PubMed ID: 24013361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab.
    Orfanoudaki E; Gazouli M; Foteinogiannopoulou K; Theodoraki E; Legaki E; Romanos I; Mouzas I; Koutroubakis IE
    Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):187-191. PubMed ID: 30543573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Infliximab Drug and Antibody Levels and Therapy Outcome in Pediatric Inflammatory Bowel Diseases.
    Ungar B; Glidai Y; Yavzori M; Picard O; Fudim E; Lahad A; Haberman Y; Shouval DS; Weintraub I; Eliakim R; Ben-Horin S; Weiss B
    J Pediatr Gastroenterol Nutr; 2018 Oct; 67(4):507-512. PubMed ID: 29901557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment.
    Imaeda H; Bamba S; Takahashi K; Fujimoto T; Ban H; Tsujikawa T; Sasaki M; Fujiyama Y; Andoh A
    J Gastroenterol; 2014 Apr; 49(4):674-82. PubMed ID: 23666424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre.
    Kolar M; Duricova D; Bortlik M; Hruba V; Machkova N; Mitrova K; Malickova K; Lukas M; Lukas M
    Dig Dis; 2017; 35(1-2):91-100. PubMed ID: 28147356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of infliximab therapeutic drug level monitoring on outcomes of patients with inflammatory bowel disease: A real-world experience from a Middle Eastern cohort.
    Azzam N; Aljebreen A; Alharbi O; Charabaty A; Alanazi M; Alkuwaykibi N; Alfaraidi J; Bashamil A; Almansour T; Almadi M
    Arab J Gastroenterol; 2021 Mar; 22(1):66-72. PubMed ID: 33632623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum Infliximab Cutoff trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease.
    Choi SY; Kang B; Choe YH
    Gut Liver; 2019 Sep; 13(5):541-548. PubMed ID: 30970435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-Year Clinical Outcomes in an IBD Cohort Who Have Previously Had Anti-TNFa Trough and Antibody Levels Assessed.
    Tighe D; Hall B; Jeyarajah SK; Smith S; Breslin N; Ryan B; McNamara D
    Inflamm Bowel Dis; 2017 Jul; 23(7):1154-1159. PubMed ID: 28486256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study.
    Warman A; Straathof JW; Derijks LJ
    Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):242-8. PubMed ID: 25569569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum-Infliximab Trough Levels in 45 Children with Inflammatory Bowel Disease on  Maintenance Treatment.
    Rolandsdotter H; Marits P; Sundin U; Wikström AC; Fagerberg UL; Finkel Y; Eberhardson M
    Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28272355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum infliximab concentrations in pediatric inflammatory bowel disease.
    Hämäläinen A; Sipponen T; Kolho KL
    Scand J Gastroenterol; 2013 Jan; 48(1):35-41. PubMed ID: 23148710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease.
    Roblin X; Marotte H; Leclerc M; Del Tedesco E; Phelip JM; Peyrin-Biroulet L; Paul S
    J Crohns Colitis; 2015 Jul; 9(7):525-31. PubMed ID: 25895875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-infliximab antibodies and low infliximab levels correlate with drug discontinuation in pediatric inflammatory bowel disease.
    Zitomersky N; Chi L; Liu E; Bray KR; Papamichael K; Cheifetz AS; Snapper SB; Bousvaros A; Silvester JA
    J Pediatr Gastroenterol Nutr; 2024 Feb; 78(2):261-271. PubMed ID: 38374555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Causes of Treatment Failure in Children With Inflammatory Bowel Disease Treated With Infliximab: A Pharmacokinetic Study.
    Naviglio S; Lacorte D; Lucafò M; Cifù A; Favretto D; Cuzzoni E; Silvestri T; Pozzi Mucelli M; Radillo O; Decorti G; Fabris M; Bramuzzo M; Taddio A; Stocco G; Alvisi P; Ventura A; Martelossi S
    J Pediatr Gastroenterol Nutr; 2019 Jan; 68(1):37-44. PubMed ID: 30211845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. INFLIXIMAB AND ADALIMUMAB SERUM TROUGH CONCENTRATIONS THRESHOLD ASSOCIATED WITH DEEP REMISSION IN INFLAMMATORY BOWEL DISEASE.
    Pascual-Marmaneu Ó; Belles-Medall MD; Ferrando-Piqueres R; Almela-Notari P; Mendoza-Aguilera M; Álvarez-Martín T
    Farm Hosp; 2021 Aug; 45(5):225-233. PubMed ID: 34806581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Use of Infliximab Trough Levels and Antibodies to Infliximab in Pediatric Patients With Inflammatory Bowel Disease.
    Merras-Salmio L; Kolho KL
    J Pediatr Gastroenterol Nutr; 2017 Feb; 64(2):272-278. PubMed ID: 27149256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease.
    van Hoeve K; Dreesen E; Hoffman I; Van Assche G; Ferrante M; Gils A; Vermeire S
    J Crohns Colitis; 2018 Nov; 12(11):1316-1325. PubMed ID: 30239644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.